Positioning ahead of March 3 business update call drove the day's rally.
Traders positioned for ImmunityBio's scheduled conference call on March 3, 2026, at 1:30 p.m. PT, where management will review full-year 2025 financial results—building on the February 23 preliminary report of 700% year-over-year revenue growth to $113 million from ANKTIVA sales—and provide clinical pipeline updates. High trading volume exceeded 24 million shares amid retail discussions on social platforms highlighting potential guidance, global partnerships in 33 countries, and debt conversion options. This extended recent momentum from trial enrollment completions and prior regulatory wins, like European authorization in February, pushing shares up nearly 11% intraday to $10.85.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.